Cyclic sulfoxides and sulfones in drug design
Advances in Heterocyclic Chemistry, ISSN: 0065-2725, Vol: 134, Page: 1-30
2021
- 29Citations
- 33Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
The present review mainly focuses on discussing lead compounds and drugs that contain cyclic sulfoxide and sulfone moieties together with appropriate consideration of the structure–activity relationships (SARs). Cyclic sulfoxides and sulfones have been found to function as important pharmacophores that are responsible for the biological activity toward a range of targets across many therapeutic areas. In particular, the sulfone is a polar moiety that offers many useful properties, including lowering the lipophilicity of a molecule, which can help to increase solubility and metabolic stability and lead to an overall improvement of ADME (absorption, distribution, metabolism and excretion) properties. In this chapter, cyclic sulfoxides and sulfones are discussed with respect to their ability to act as conformational constraints, H-bond acceptor and electron-withdrawing elements, including application as bioisosteres of ketone and carboxylic acid functionalities. In addition, the sulfone moiety can reduce the basicity of proximal amines, leading to modulation of their overall basicity and, in many cases, improving the toxicity profile. This review outlines some of the recent examples of applications of cyclic sulfoxides and sulfones in medicinal chemistry. In addition, we highlight the roles that the cyclic sulfones play in preclinical and clinical compounds and marketed drugs.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S006527252030060X; http://dx.doi.org/10.1016/bs.aihch.2020.10.003; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85097776840&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S006527252030060X; https://dx.doi.org/10.1016/bs.aihch.2020.10.003
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know